Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs - United States
doi 10.1097/cad.0000000000000159
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

The Prospects for Cisplatin and Nab-Paclitaxel Combination Therapy in Patients With Pre-Treated Triple-Negative Breast Cancer. Description of the Clinical Case.

Medical Council
2018English

Quality-Adjusted Survival With Nab -Paclitaxel vs Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis

Clinical Breast Cancer
Cancer ResearchOncology
2018English

Role of Nab-Paclitaxel in Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials

Oncotarget
Oncology
2017English

The Results of a Study of Chemotherapy With Bevacizumab, Oxaliplatin and Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2017English

Triple-Negative Breast Cancer

2018English

Feasibility Study of Personalized Peptide Vaccination for Metastatic Recurrent Triple-Negative Breast Cancer Patients

Breast Cancer Research
Cancer ResearchOncology
2014English

Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer

Clinical Cancer Reviews
2009English

Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy